Loading stock data…
FLGT
$14.13-1.06 (-6.98%)
Market ClosedLast close May 1
Fulgent Genetics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fulgent Genetics, Inc. in the Healthcare sector is trading at $14.13. The stock is currently near its 52-week low of $13.46, remaining 36.3% below its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why FLGT maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.13
Potential Upside
5%
Whystock Fair Value$14.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Buy
Mean target$26.00+84.0%
Range$22.00 – $30.00
Fundamentals
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$508.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.44%
Volume
Today's trading volume
1.44M
Recent News
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Despite a dip in revenue, Fulgent Genetics Inc (FLGT) focuses on strategic acquisitions and pipeline advancements to bolster future growth.
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Fulgent Genetics, Inc.'s Q1 2026 earnings call
Fulgent Genetics Q1 Earnings Call Highlights
Fulgent Genetics (NASDAQ:FLGT) reported first-quarter 2026 revenue of $71.1 million as the company worked through a planned decline in testing volumes from its largest customer while integrating the recently completed acquisitions of Bako Diagnostics and StrataDX. First-quarter revenue pressured by
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
iRhythm Holdings, Inc. (IRTC) Reports Q1 Loss, Tops Revenue Estimates
IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +37.78% and +2.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?